Organogenesis Holdings Future Growth
Future criteria checks 3/6
Organogenesis Holdings is forecast to grow earnings and revenue by 61.5% and 5.5% per annum respectively. EPS is expected to grow by 60.7% per annum. Return on equity is forecast to be -0.8% in 3 years.
Key information
61.5%
Earnings growth rate
60.7%
EPS growth rate
| Biotechs earnings growth | 25.1% |
| Revenue growth rate | 5.5% |
| Future return on equity | -0.8% |
| Analyst coverage | Low |
| Last updated | 13 May 2024 |
Recent future growth updates
Recent updates
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly
Nov 30Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate
Sep 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 508 | 17 | N/A | 40 | 3 |
| 12/31/2025 | 477 | 7 | N/A | 29 | 3 |
| 12/31/2024 | 456 | -2 | N/A | 26 | 3 |
| 3/31/2024 | 435 | 6 | 7 | 26 | N/A |
| 12/31/2023 | 433 | 5 | 7 | 31 | N/A |
| 9/30/2023 | 449 | 13 | -4 | 28 | N/A |
| 6/30/2023 | 457 | 10 | -19 | 17 | N/A |
| 3/31/2023 | 461 | 13 | -16 | 18 | N/A |
| 12/31/2022 | 451 | 16 | -9 | 25 | N/A |
| 9/30/2022 | 463 | 59 | 7 | 35 | N/A |
| 6/30/2022 | 460 | 71 | 23 | 57 | N/A |
| 3/31/2022 | 462 | 83 | 32 | 65 | N/A |
| 12/31/2021 | 467 | 94 | 31 | 62 | N/A |
| 9/30/2021 | 446 | 62 | 36 | 67 | N/A |
| 6/30/2021 | 433 | 69 | 28 | 48 | N/A |
| 3/31/2021 | 379 | 43 | 3 | 21 | N/A |
| 12/31/2020 | 338 | 17 | -12 | 5 | N/A |
| 9/30/2020 | 306 | -5 | -40 | -24 | N/A |
| 6/30/2020 | 270 | -37 | -50 | -38 | N/A |
| 3/31/2020 | 266 | -42 | -51 | -41 | N/A |
| 12/31/2019 | 261 | -39 | -40 | -34 | N/A |
| 9/30/2019 | 250 | -46 | -48 | -45 | N/A |
| 6/30/2019 | 236 | -48 | -65 | -62 | N/A |
| 3/31/2019 | 215 | -58 | -68 | -66 | N/A |
| 12/31/2018 | 193 | -65 | -62 | -61 | N/A |
| 9/30/2018 | 183 | -60 | -48 | -46 | N/A |
| 6/30/2018 | 184 | -52 | -27 | -25 | N/A |
| 3/31/2018 | 187 | -32 | -11 | -9 | N/A |
| 12/31/2017 | 199 | -9 | N/A | -3 | N/A |
| 12/31/2016 | 139 | -17 | N/A | -5 | N/A |
| 12/31/2015 | 99 | -24 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORGO's forecast earnings growth (61.5% per year) is above the savings rate (2.4%).
Earnings vs Market: ORGO's earnings (61.5% per year) are forecast to grow faster than the US market (14.6% per year).
High Growth Earnings: ORGO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ORGO's revenue (5.5% per year) is forecast to grow slower than the US market (8.4% per year).
High Growth Revenue: ORGO's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORGO is forecast to be unprofitable in 3 years.